Fred Hutch Cancer Center | Strategic Alliance Partners

December 19, 2024

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

December 12, 2024

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

November 11, 2024

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

November 11, 2024

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

November 11, 2024

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

November 11, 2024

Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.

November 11, 2024

Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.

November 06, 2024

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

November 05, 2024

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.

October 08, 2024

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

September 24, 2024

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

September 16, 2024

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

September 13, 2024

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

September 02, 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

August 29, 2024

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.

August 28, 2024

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

August 27, 2024

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

August 26, 2024

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

August 16, 2024

Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.